Recent Company News

• 10:01 AM ET Jun 25, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (324 total)

• 10:03 AM ET Jun 11, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (204 total)

• 10:05 AM ET Jun 05, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (106 total)

• 02:11 PM ET May 29, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 31-May

• 02:22 PM ET May 22, 2026
  

  StreetAccount Summary: Notable Drug Events expected for the week of 24-May

• 05:15 PM ET May 21, 2026
  

  Bicycle Therapeutics to present initial Duravelo-2 data at 2026 ASCO annual meeting ($4.45, 0.00)

• 08:22 AM ET Apr 30, 2026
  

  StreetAccount Summary - US Pre-market trading

• 07:15 AM ET Apr 30, 2026
  

  Bicycle Therapeutics reports Q1 EPS ($0.87) vs FactSet ($0.62) [11 est, ($0.80)-(0.31)] ($4.73, 0.00)

• 07:03 AM ET Apr 20, 2026
  

  Bicycle Therapeutics provides update on Nuzefatide Pevedotin and EphA2 pipeline at the AACR Annual Meeting 2026 ($5.33, 0.00)

• 10:00 AM ET Mar 24, 2026
  

  StreetAccount Summary: Stocks reaching new 52-week highs/lows (147 total)